Palivizumab (Systemic)
Brand Names : Synagis
Category- Immunizing agent (passive)
DescriptionPalivizumab (pal-i-VI-zu-mab) belongs to a group of medicines known as
immunizing agents. Palivizumab is used to prevent infection caused by respiratory
syncytial virus (RSV). This medicine works by giving your body the antibodies
it needs to protect it against RSV infection.
RSV infection can cause serious problems that affect the lungs, such as
pneumonia and bronchitis, and in severe cases even can cause death. These
problems are more likely to occur in infants and children younger than 6 months
of age with chronic lung disease and breathing problems and in babies who
were premature.
Palivizumab is used to prevent serious lower respiratory tract infection
caused by the RSV.
Onset of RSV activity usually occurs in November and continues through
April, but it may begin earlier or continue later in certain communities.
A good way to help prevent RSV infection is to receive palivizumab before
the start of the RSV season.
Palivizumab is to be administered only by or under the supervision of your
doctor or other health care professional. It is available in the following
dosage form:
Parenteral
-
Injection (U.S.)
Brand NamesSome commonly used brand names are:
In the U.S.—
|
